Tuesday - July 1, 2025
Single infusion of CARVYKTI (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
June 03, 2025
NEW BRUNSWICK, New Jersey, June 3 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:

* * *

Single infusion of CARVYKTI(r) (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma

*

CHICAGO (June 3, 2025) - Johnson & Johnson announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products